Symbol="PRLD"
AssetType="Common Stock"
Name="Prelude TherapeuticsÂ Inc"
Description="Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware."
CIK="1678660"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="200 POWDER MILL ROAD, WILMINGTON, DE, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="208758000"
EBITDA="-121072000"
PERatio="None"
PEGRatio="None"
BookValue="3.668"
DividendPerShare="0"
DividendYield="0"
EPS="-2.35"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.319"
ReturnOnEquityTTM="-0.52"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-2.35"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="10.75"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.145"
EVToRevenue="-"
EVToEBITDA="-0.214"
Beta="0.352"
num_52WeekHigh="8.9"
num_52WeekLow="3.7"
num_50DayMovingAverage="5.0"
num_200DayMovingAverage="5.97"
SharesOutstanding="39601500"
DividendDate="None"
ExDividendDate="None"
symbol="PRLD"
open="4.04"
high="4.11"
low="3.70"
price="3.91"
volume="71922.00"
latest_trading_day="2023-07-31"
previous_close="3.98"
change="-0.07"
change_percent="-1.7588%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="50"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="50"
Volume_recent_avg="112242"
Change_recent_avg="-0.01"
Delta_recent_avg="0.49"
Variance_recent_avg="0.24"
Change_ratio_recent_avg="-0.43"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="50"
Aroon_momentum_negative="50"
image_negative_thumbnail_id_1="97"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0079.jpeg"
image_negative_thumbnail_id_2="512"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0093.jpeg"
image_neutral_thumbnail_id_1="587"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0012.jpeg"
image_neutral_thumbnail_id_2="535"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0064.jpeg"
image_positive_thumbnail_id_1="669"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0039.jpeg"
image_positive_thumbnail_id_2="679"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0029.jpeg"
image_professor_thumbnail_id_1="1175"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0009.jpeg"
image_professor_thumbnail_id_2="1198"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0032.jpeg"
